SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
YORDON JEFFREY

(Last) (First) (Middle)
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600

(Street)
BUFFALO NY 14203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Athenex, Inc. [ ATNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/03/2022 M 12,500 A (1) 249,606 D
Common Stock 08/03/2022 F 3,663 D $0.5806 245,943 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $9 06/19/2018 06/19/2026 Common Stock 150,000 150,000 D
Stock Option (Right to Buy) $11 06/13/2020 06/13/2027 Common Stock 211,820 211,820 D
Stock Option (Right to Buy) $17.3 03/27/2022 03/27/2028 Common Stock 100,000 100,000 D
Stock Option (Right to Buy) $13.17 (2) 02/28/2029 Common Stock 100,000 100,000 D
Stock Option (Right to Buy) $12.45 (3) 06/05/2030 Common Stock 100,000 100,000 D
Stock Option (Right to Buy) $3.8 (4) 08/05/2031 Common Stock 50,000 50,000 D
Restricted Stock Units (1) 08/03/2022 M 12,500 (5) (5) Common Stock 12,500 $0.00 37,500 D
Stock Option (Right to Buy) $0.6655 (6) 07/20/2032 Common Stock 150,000 150,000 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of stock.
2. This option vests in four equal annual installments beginning on February 28, 2020.
3. This option vests in four equal annual installments beginning on June 5, 2021.
4. This option vests in four equal annual installments beginning on August 3, 2022.
5. The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
6. This option vests in four equal annual installments beginning on July 20, 2023.
Remarks:
COO, and President, Athenex Pharmaceutical Division.
/s/Staci Holquist, Attorney-in-Fact 08/15/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.